Not provided
Not provided
Not provided
Not provided
Sponsor business decision, not safety related
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will look at the safety of treating patients with heart attack with mild hypothermia induced using a system of automated peritoneal lavage. The hypothesis is that the Velomedix Automated Peritoneal Lavage System can treat patients with heart attack safely and with adequate performance.
The study aims to determine the safety and feasibility of using the Velomedix Automated Peritoneal Lavage System to treat patients with STEMI using therapeutic hypothermia. Patients will undergo cooling, maintenance and rewarming and applicable data will be gathered on device performance and patient safety. Patient temperature and vital signs will be monitored in addition to various laboratory values. Adverse event reporting will take place at multiple time intervals and follow-up will continue out to 6-months.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Therapeutic Hypothermia Treatment | Experimental |
| |
| No Hypothermia Treatment | Active Comparator | control group is no hypothermia treatment |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Velomedix APLS device | Device | Velomedix, Automated Peritoneal Lavage System |
|
| Measure | Description | Time Frame |
|---|---|---|
| Composite of new-onset SAEs | Composite of new-onset serious adverse events, specifically death, ischemia driven target vessel revascularization (TVR), recurrent MI, pneumonia, sepsis, ventricular tachycardia or fibrillation requiring cardioversion, renal failure, peritonitis and significant bleeding. | 30 days |
| Measure | Description | Time Frame |
|---|---|---|
| MACE rate | MACE (cardiac related mortality, recurrent MI, or ischemia driven target vessel revascularization (PCI or CABG) at 30 days | 30 days |
| All cause mortality | All cause mortality through 6 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Gregg Stone, MD | New York Presbyterian Hospital / Columbia University Medical Center | Principal Investigator |
| Graham Nichol, MD | University of Washington, Harberview Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Heart Center Research, LLC | Huntsville | Alabama | 35801 | United States | ||
| LA County USC Hospital |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 25699687 | Derived | Nichol G, Strickland W, Shavelle D, Maehara A, Ben-Yehuda O, Genereux P, Dressler O, Parvataneni R, Nichols M, McPherson J, Barbeau G, Laddu A, Elrod JA, Tully GW, Ivanhoe R, Stone GW; VELOCITY Investigators. Prospective, multicenter, randomized, controlled pilot trial of peritoneal hypothermia in patients with ST-segment- elevation myocardial infarction. Circ Cardiovasc Interv. 2015 Mar;8(3):e001965. doi: 10.1161/CIRCINTERVENTIONS.114.001965. Epub 2015 Feb 19. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D007035 | Hypothermia |
| ID | Term |
|---|---|
| D001832 | Body Temperature Changes |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| No Hypothermia Treatment | Other |
|
| 6 months |
| Myocardial infarct size | Myocardial infarct size at 3 days post-procedure | 3 days |
| Los Angeles |
| California |
| United States |
| Northeast Georgia Medical Center | Gainesville | Georgia | 30501 | United States |
| Ochsner Medical Center | New Orleans | Louisiana | United States |
| Vanderbilt University | Nashville | Tennessee | United States |
| Victoria Heart Institute Foundation | Victoria | British Columbia | VSR 4R2, | Canada |
| Institut Universitaire de cardiologie et pneumologie de Québec (Hopital Laval) | Québec | Quebec | G1V 4G5 | Canada |